Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement help dialysis patients?

NCT ID NCT07249229

Disease control Sponsor: Darya Chamani Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking oral L-carnitine (a natural supplement) three times a week for three months could reduce inflammation and improve nutrition in 50 adults with advanced kidney failure on chronic hemodialysis. Participants were randomly assigned to receive either L-carnitine or a placebo. Researchers measured changes in blood markers of inflammation and nutrition to see if the supplement offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-carnitine
What this could lead to
If it works, this could point toward a simple supplement to help manage inflammation and nutrition in dialysis patients.
What could go wrong
This is a small, early-phase trial (50 people) testing only short-term effects. Results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Nov 2020

Finished

Mar 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * On maintenance hemodialysis for at least 6 months * Clinically stable for ≥ 3 months * No hospitalization in the preceding 3 months * Willingness to provide written informed consent and comply with study procedures Exclusion Criteria: * Use of statins, erythropoietin, corticosteroids, NSAIDs, or other anti-inflammatory/lipid-lowering agents within the previous 3 months * Active infection, inflammatory disease, malignancy, or severe hepatic dysfunction * Pregnancy or breastfeeding * Participation in another clinical trial within the preceding 3 months * Uncontrolled comorbidities (e.g., uncontrolled diabetes or hypertension) * Acute cardiovascular events within the past 6 months * Planned kidney transplantation during the study period * Anticipated poor compliance * Use of medications that could affect inflammatory or lipid parameters * History of hypersensitivity to L-carnitine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Inflammation Malnutrition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease (ESRD) Hemodialysis

Contacts and locations

Locations

  • Bu Ali Hospital

    Tehran, Tehran Province, 1711734365, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.